1 / 4

Comparison of Endothelial Progenitor Cell-Capturing Stents Versus Drug-Eluting Stents for High-Risk Restenosis Lesions

Explore the non-inferiority of endothelial progenitor cell-capturing stents (ECS) versus drug-eluting stents (DES) in patients undergoing PCI for high-risk restenosis lesions. This multicenter, randomized study assesses TLF and MACE endpoints at 1 year. Results indicate ECS did not match DES in restenosis prevention post-PCI of high-risk restenosis lesions. Reference: Klomp JACC Interv 2011;4:896-904.

kyra-cline
Download Presentation

Comparison of Endothelial Progenitor Cell-Capturing Stents Versus Drug-Eluting Stents for High-Risk Restenosis Lesions

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. ECS versus DES: TRIAS-HR 1 year Objective: to demonstrate non-inferiority of endothelialprogenitorcellcapturingstents(ECS) versus drugelutingstents (DES)Study: multicenter, randomizedstudyPopulation: patients with PCI of at least 1 targetlesionat high-risk of restenosis(smallvessel ≤ 2,8mm, lesionlength ≥ 20mm, CTO or lesion in DM patient)Endpoint: TLF and MACE: Cardiacdeath, MI or TLR

  2. ECS versus DES: TRIAS-HR 1 year

  3. ECS versus DES: TRIAS-HR 1 year

  4. ECS versus DES: TRIAS-HR 1 year Conclusion ECS was not able to competewith DES in terms of restenosispreventionafter PCI of high-riskrestenosislesions Klomp JACC Interv 2011;4:896-904

More Related